Published in J Clin Oncol on July 19, 2010
Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol (2011) 2.90
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer (2013) 1.96
STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res (2011) 1.62
IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol Cancer (2011) 1.19
Experimental mouse tumour models: what can be learnt about human cancer immunology? Nat Rev Immunol (2011) 1.17
Inflammasomes in cancer: a double-edged sword. Protein Cell (2014) 1.01
Interleukin-17: a promoter in colorectal cancer progression. Clin Dev Immunol (2013) 1.00
Harnessing the antitumor potential of macrophages for cancer immunotherapy. Oncoimmunology (2013) 0.93
Profiles of gene polymorphisms in cytokines and Toll-like receptors with higher risk for gastric cancer. Dig Dis Sci (2012) 0.91
Prognostic value of innate and adaptive immunity in colorectal cancer. World J Gastroenterol (2013) 0.90
Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res (2014) 0.88
High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression. J Cell Mol Med (2013) 0.88
Role of nuclear receptor NR4A2 in gastrointestinal inflammation and cancers. World J Gastroenterol (2012) 0.85
Expression of interleukin-22/STAT3 signaling pathway in ulcerative colitis and related carcinogenesis. World J Gastroenterol (2013) 0.85
No relationship between the distribution of mast cells and the survival of stage IIIB colon cancer patients. J Transl Med (2011) 0.84
Stress- and Rho-activated ZO-1-associated nucleic acid binding protein binding to p21 mRNA mediates stabilization, translation, and cell survival. Proc Natl Acad Sci U S A (2012) 0.83
How do cytokines trigger genomic instability? J Biomed Biotechnol (2012) 0.82
Immune reaction and colorectal cancer: friends or foes? World J Gastroenterol (2014) 0.81
Serotonin transporter gene (SLC6A4) variations are associated with poor survival in colorectal cancer patients. PLoS One (2012) 0.80
Oxidative DNA damage caused by inflammation may link to stress-induced non-targeted effects. Cancer Lett (2013) 0.79
HLA class I: an unexpected role in integrin β4 signaling in endothelial cells. Hum Immunol (2012) 0.78
Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions. Carcinogenesis (2015) 0.77
Systemic immune-inflammation index, thymidine phosphorylase and survival of localized gastric cancer patients after curative resection. Oncotarget (2016) 0.77
Radiopharmaceuticals as probes to characterize tumour tissue. Eur J Nucl Med Mol Imaging (2015) 0.76
Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer. PLoS One (2013) 0.76
Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis. Sci Rep (2016) 0.75
Increased transforming growth factor β and interleukin 10 transcripts in peripheral blood mononuclear cells of colorectal cancer patients. Contemp Oncol (Pozn) (2017) 0.75
The Differential Expression and Function of the Inflammatory Chemokine Receptor CXCR5 in Benign Prostatic Hyperplasia and Prostate Cancer. Int J Med Sci (2015) 0.75
Helicobacter Pylori Promote B7-H1 Expression by Suppressing miR-152 and miR-200b in Gastric Cancer Cells. PLoS One (2017) 0.75
Sleep Duration and Cancer in the NIH-AARP Diet and Health Study Cohort. PLoS One (2016) 0.75
Impact Of Circulating T Helper 1 And 17 Cells in the Blood on Regional Lymph Node Invasion in Colorectal Cancer. J Cancer (2017) 0.75
Systemic immune-inflammation index predicts the clinical outcome in patients with nasopharyngeal carcinoma: a propensity score-matched analysis. Oncotarget (2017) 0.75
Cancer-related inflammation. Nature (2008) 34.21
Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell (2004) 29.32
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 25.63
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 22.57
Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med (1999) 17.30
Shock and tissue injury induced by recombinant human cachectin. Science (1986) 16.24
Biologic basis for interleukin-1 in disease. Blood (1996) 16.04
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
The B7 family revisited. Annu Rev Immunol (2005) 13.51
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology (1990) 11.22
Primary liver cancer: worldwide incidence and trends. Gastroenterology (2004) 11.21
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (1999) 11.04
IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol (1991) 11.04
IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell (2005) 8.78
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 7.78
Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med (1993) 7.67
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
Inhibition of NF-kappa B by sodium salicylate and aspirin. Science (1994) 7.60
Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med (2009) 7.53
A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med (2009) 7.45
Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol (2003) 6.95
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67
IL-23 promotes tumour incidence and growth. Nature (2006) 6.30
Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci U S A (2004) 5.89
Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science (2007) 5.54
Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics (1985) 5.30
Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol (2007) 5.28
Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest (2008) 5.26
IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 5.05
Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell (2009) 4.56
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity (2004) 4.48
Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell (2008) 4.43
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst (2002) 4.43
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res (2007) 4.41
Inflammation, atrophy, and gastric cancer. J Clin Invest (2007) 4.29
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28
Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology (2003) 4.10
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Sexually transmitted infection as a cause of anal cancer. N Engl J Med (1997) 4.05
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol (2002) 3.72
Immune therapy for cancer. Annu Rev Immunol (2009) 3.71
Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest (1995) 3.43
Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res (1999) 3.40
Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res (2006) 3.38
Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest (2008) 3.37
Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst (2009) 3.19
Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity (1996) 3.18
A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst (2007) 2.95
Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med (1995) 2.64
A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell (2009) 2.64
Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res (2009) 2.62
The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med (1998) 2.55
Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice. J Immunol (2000) 2.54
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) (2009) 2.46
Th17 cells: a new fate for differentiating helper T cells. Immunol Res (2008) 2.45
T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res (2009) 2.43
B lymphocytes induce the formation of follicular dendritic cell clusters in a lymphotoxin alpha-dependent fashion. J Exp Med (1998) 2.32
Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther (2000) 2.25
CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res (2005) 2.20
Role of gamma interferon in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Infect Immun (1999) 2.14
Immune pathogenesis of hepatocellular carcinoma. J Exp Med (1998) 2.11
The role of T cell subsets and cytokines in the pathogenesis of Helicobacter pylori gastritis in mice. J Immunol (2001) 2.08
Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology (2003) 2.06
Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta (2009) 1.75
The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature (2001) 1.71
Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol (2003) 1.71
NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res (2009) 1.50
Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol (2002) 1.33
Evaluating the impact of human papillomavirus vaccines. Vaccine (2009) 1.32
Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett (2008) 1.31
Helicobacter pylori--not a good bug after all! N Engl J Med (2001) 1.30
Helicobacter pylori cytotoxin-associated gene A activates the signal transducer and activator of transcription 3 pathway in vitro and in vivo. Cancer Res (2009) 1.28
Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res (2005) 1.25
Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet (1995) 1.25
Rapid development of severe hyperplastic gastritis with gastric epithelial dedifferentiation in Helicobacter felis-infected IL-10(-/-) mice. Am J Pathol (1998) 1.24
Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion. J Surg Oncol (2009) 0.94
Risk of cancer in ulcerative colitis. J Gastrointest Surg (1999) 0.89
Decreased NKG2D expression on CD8+ T cell is involved in immune evasion in patients with gastric cancer. Clin Cancer Res (2007) 0.85
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Cancer immunotherapy comes of age. Nature (2011) 12.35
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity (2007) 4.49
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Immune therapy for cancer. Annu Rev Immunol (2009) 3.71
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov (2013) 3.25
Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol (2010) 3.03
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol (2011) 2.90
Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res (2009) 2.62
Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol (2003) 2.36
Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med (2003) 2.36
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J Clin Invest (2007) 2.24
IAP inhibitors enhance co-stimulation to promote tumor immunity. J Exp Med (2010) 2.07
Infection-mimicking materials to program dendritic cells in situ. Nat Mater (2009) 2.00
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med (2013) 1.96
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A (2006) 1.88
In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci Transl Med (2009) 1.65
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A (2008) 1.59
Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell (2012) 1.59
Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev (2008) 1.34
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A (2009) 1.34
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest (2013) 1.30
Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and twist signaling in the tumor microenvironment. Cancer Res (2008) 1.29
A dual role for the immune response in a mouse model of inflammation-associated lung cancer. J Clin Invest (2011) 1.25
Ex vivo characterization and isolation of rare memory B cells with antigen tetramers. Blood (2011) 1.21
Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms. J Exp Med (2009) 1.15
Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A (2003) 1.14
Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother (2012) 1.14
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci U S A (2002) 1.12
Prostate cancer immunotherapy. Clin Cancer Res (2011) 1.11
Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood (2003) 1.09
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 1.08
CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc Natl Acad Sci U S A (2003) 1.06
Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res (2010) 1.05
Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants. Cancer Res (2014) 1.04
IL-3 is required for increases in blood basophils in nematode infection in mice and can enhance IgE-dependent IL-4 production by basophils in vitro. Lab Invest (2008) 1.01
Inciting inflammation: the RAGE about tumor promotion. J Exp Med (2008) 0.99
Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. Blood (2008) 0.98
CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity. Exp Dermatol (2005) 0.96
In vivo evidence for the role of GM-CSF as a mediator in acute pancreatitis-associated lung injury. Am J Physiol Lung Cell Mol Physiol (2002) 0.95
Combinatorial cancer immunotherapy. Adv Immunol (2006) 0.93
IL-7 induces myelopoiesis and erythropoiesis. J Immunol (2007) 0.93
CTLA-4 blockade: unveiling immune regulation. J Clin Oncol (2004) 0.93
Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation. Cancer Res (2002) 0.92
MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun (2003) 0.92
The immune response to tumors. Curr Protoc Immunol (2009) 0.91
Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood (2012) 0.91
The biologic importance of tumor-infiltrating lymphocytes. J Cutan Pathol (2010) 0.90
Capitalizing on the immunogenicity of dying tumor cells. Clin Cancer Res (2008) 0.89
Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells. Blood (2007) 0.89
Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients. Oncoimmunology (2012) 0.87
Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clin Cancer Res (2008) 0.87
Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells. J Exp Med (2005) 0.86
Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol (2008) 0.86
Role of GM-CSF signaling in cell-based tumor immunization. Blood (2009) 0.86
Triggering tumor immunity through angiogenesis targeting. Clin Cancer Res (2007) 0.86
High-resolution array CGH and gene expression profiling of alveolar soft part sarcoma. Clin Cancer Res (2014) 0.85
GM-CSF-independent CD1a expression in epidermal Langerhans cells: evidence from human CD1A genome-transgenic mice. J Invest Dermatol (2011) 0.84
Anti-angiogenesis immunotherapy. Hum Vaccin (2011) 0.83
A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma. J Hematol Oncol (2014) 0.83
NF-kappaB fans the flames of lung carcinogenesis. Cancer Prev Res (Phila) (2010) 0.82
Disruption of CD8+ Treg activity results in expansion of T follicular helper cells and enhanced antitumor immunity. Cancer Immunol Res (2013) 0.82
Erythropoietin receptor haploinsufficiency and in vivo interplay with granulocyte-macrophage colony-stimulating factor and interleukin 3. Blood (2002) 0.82
Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival. Vaccine (2009) 0.81
Granulocyte-macrophage colony stimulating factor and inflammatory bowel disease: establishing a connection. Gastroenterology (2011) 0.81
Tumour immunology. Curr Opin Immunol (2013) 0.79
Interleukin-3 and c-Kit/stem cell factor are required for normal eosinophil responses in mice infected with Strongyloides venezuelensis. Lab Invest (2006) 0.78
Treatment with GM-CSF secreting myeloid leukemia cell vaccine prior to autologous-BMT improves the survival of leukemia-challenged mice. Biol Blood Marrow Transplant (2010) 0.76
Erratum: Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2. Nat Commun (2017) 0.75
Cancer immunology research: a one-year anniversary. Cancer Immunol Res (2014) 0.75
Cancer Immunology Research: A Two-Year Anniversary. Cancer Immunol Res (2015) 0.75